Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 810 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR De qué manera el seguimiento de los síntomas mejora la atención... May 6, 2021 Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... August 20, 2019 What to Know About Using Activated Charcoal During Cancer December 21, 2023 From smouldering ash to a gleaming temple for cancer research: The... April 26, 2023 Load more HOT NEWS Immune interception represents an exciting opportunity to stop cancer in its... Advances in Gynaecological Cancer Research Could Change the Treatment Landscape Opinion: ‘We’re making headway, but we can’t be complacent’ Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,...
